OKUR OnKure Therapeutics, Inc.
USHealthcareAs of 2026-08-24
Why OKUR matters now
OnKure Therapeutics, Inc. (OKUR) is a US stock in Healthcare. The latest InvestLog snapshot shows $3.89 with -1.27% on the session and $157.5M in market capitalization; recent performance reads 1-month +35.76% and YTD +54.48%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-15.2M, and EPS of $-1.11. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -82.9%.
The latest indexable market news headline is "OnKure Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $35.00; recent insider activity includes Carruthers R Michael filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
0.33
P/S
0.00
EV/EBITDA
2.25
DCF Value
$4.23
FCF Yield
-82.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-61.0%
ROA
-29.6%
ROIC
-33.3%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-15.2M | $-1.11 |
| Q4 2025 | $0.00 | $-13.5M | $-0.99 |
| FY 2025 | $0.00 | $-59.5M | $-4.40 |
| Q3 2025 | $0.00 | $-14.7M | $-1.09 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$35.00
Target (Median)
$35.00
Target Range
$35.00 - $35.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.28
OnKure, Inc., established in 2011 and based in Boulder, Colorado, operates as a biopharmaceutical company primarily engaged in the creation and advancement of precise therapeutic agents for cancer. A core area of their research centers on developing highly selective inhibitors for histone deacetylases. Their current pipeline features OKI-179, an inhibitor specifically engineered to combat a wide spectrum of malignancies, including both blood-related cancers and solid tumor formations.